Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gastrointestinal Cancer Excellence Forum

Gastrointestinal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Ignacio Garrido-Laguna, MD, Huntsman Cancer Institute
Videos
Entrectinib Yields Durable Responses, Manageable Safety in NTRK Fusion-Positive Gastrointestinal Cancers
07/03/2022
Ignacio Garrido-Laguna, MD, discusses findings from an updated integrated analysis exploring entrectinib in patients with NTRK fusion-positive gastrointestinal cancer.
Ignacio Garrido-Laguna, MD, discusses findings from an updated integrated analysis exploring entrectinib in patients with NTRK fusion-positive gastrointestinal cancer.
Ignacio Garrido-Laguna, MD,...
07/03/2022
Oncology
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
Videos
Overlap Between HER2 and PD-L1 Expression in Trastuzumab-Refractory Gastric Cancer or GEJ Adenocarcinoma
07/02/2022
Yelena Janjigian, MD, discusses findings from a preliminary biomarker analysis of the ongoing DESTINY-Gastric03 trial, which explored concordance between local and central HER2 testing and overlap of PD-L1 and HER2 expression in gastric...
Yelena Janjigian, MD, discusses findings from a preliminary biomarker analysis of the ongoing DESTINY-Gastric03 trial, which explored concordance between local and central HER2 testing and overlap of PD-L1 and HER2 expression in gastric...
Yelena Janjigian, MD, discusses...
07/02/2022
Oncology
Andrea Casadei-Gardini, MD, San Raffaele Hospital
Videos
Lenvatinib Demonstrates Significant Benefit vs Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
07/02/2022
Andrea Casadei-Gardini, MD, discusses findings from an international study examining atezolizumab plus bevacizumab vs lenvatinib or sorafenib in patients with non-viral unresectable hepatocellular carcinoma.
Andrea Casadei-Gardini, MD, discusses findings from an international study examining atezolizumab plus bevacizumab vs lenvatinib or sorafenib in patients with non-viral unresectable hepatocellular carcinoma.
Andrea Casadei-Gardini, MD,...
07/02/2022
Oncology
Firas Baidoun, MD, Cleveland Clinic
Videos
Liver Transplant Associated With Improved OS vs Systemic Therapy Alone for Non-Metastatic Hepatocellular Carcinoma
07/02/2022
Firas Baidoun, MD, discusses findings from a study that compared survival outcomes between upfront liver transplant, liver transplant with bridge systemic therapy, and systemic therapy only, for non-metastatic hepatocellular carcinoma.
Firas Baidoun, MD, discusses findings from a study that compared survival outcomes between upfront liver transplant, liver transplant with bridge systemic therapy, and systemic therapy only, for non-metastatic hepatocellular carcinoma.
Firas Baidoun, MD, discusses...
07/02/2022
Oncology
Matthieu Faron, MD, Institut de Cancérologie Gustave Roussy
Videos
Neoadjuvant Chemotherapy or Chemoradiotherapy Outperform Surgery for Esophageal/GEJ Carcinoma
07/02/2022
Matthieu Faron, MD, discusses findings from an individual participant data network meta-analysis which identified the best neoadjuvant treatment for patients with esophageal or GEJ carcinoma across prespecified subgroups.
Matthieu Faron, MD, discusses findings from an individual participant data network meta-analysis which identified the best neoadjuvant treatment for patients with esophageal or GEJ carcinoma across prespecified subgroups.
Matthieu Faron, MD, discusses...
07/02/2022
Oncology
Vivian Strong, MD, Memorial Sloan Kettering Cancer Center
Videos
Encouraging a Collaborative Oncologic Environment for Novel Gastric Cancer Treatment 
03/30/2022
Vivian Strong, MD, discusses the need of surgeons working more closely with medical oncologists, GI experts, and basic scientists in order to push novel approaches forward for gastric cancer treatment.
Vivian Strong, MD, discusses the need of surgeons working more closely with medical oncologists, GI experts, and basic scientists in order to push novel approaches forward for gastric cancer treatment.
Vivian Strong, MD, discusses the...
03/30/2022
Oncology
Dr Gibson
Videos
Dr Gibson Reviews Breakthroughs With HER2, Immunotherapy for Esophageal GC
03/29/2022
Michael Gibson, MD, PhD, shares an overview of novel breakthroughs and progress with HER2 and immunotherapy targets to treat esophageal gastric cancer at the 2022 GDU GI Meeting.
Michael Gibson, MD, PhD, shares an overview of novel breakthroughs and progress with HER2 and immunotherapy targets to treat esophageal gastric cancer at the 2022 GDU GI Meeting.
Michael Gibson, MD, PhD, shares...
03/29/2022
Oncology
Dr Lieu
Podcasts
Dr Lieu Talks ctDNA to Guide CRC Treatment
03/29/2022
Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC at the 2022 GDU GI Meeting.
Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC at the 2022 GDU GI Meeting.
Christopher Lieu, MD, University...
03/29/2022
Oncology
morris
Videos
Dr Morris Talks KRAS G12C Mutated CRC
03/26/2022
Van Morris, MD, MD Anderson Cancer Center, discusses KRAS G12C mutated colorectal cancer at the 2022 GDU GI Meeting.
Van Morris, MD, MD Anderson Cancer Center, discusses KRAS G12C mutated colorectal cancer at the 2022 GDU GI Meeting.
Van Morris, MD, MD Anderson...
03/26/2022
Oncology

Advertisement

Advertisement

Advertisement

Section Editor

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center, New York

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement